NEW DELHI – In a move that could cost India's generics industry more than $1 billion, the European Commission (EC) has banned 700 Indian generic drugs, based on flaws detected during inspections of clinical trials conducted by Hyderabad-based contract research organization GVK Biosciences Ltd.